Theravance Biopharma, Inc. filings document operating results, material events, governance matters, and portfolio disclosures for a Cayman Islands biopharmaceutical issuer. Form 8-K reports furnish quarterly and annual financial updates, YUPELRI collaboration revenue, business updates, Regulation FD materials, and financial-condition disclosures tied to the company’s therapeutics business.
The filing record also covers product and intellectual-property matters, including a Hatch-Waxman settlement resolving ANDA patent litigation involving YUPELRI® (revefenacin) inhalation solution. Other disclosures address the ampreloxetine Phase 3 CYPRESS outcome, costs associated with organizational restructuring and program wind-down activities, annual general meeting voting matters, director elections, and proxy governance.
Theravance Biopharma reported that its Phase 3 CYPRESS trial of ampreloxetine in neurogenic orthostatic hypotension did not meet the primary OHSA composite endpoint, and the program will be wound down. The Board’s Strategic Review Committee is accelerating its evaluation of alternatives, including a possible sale of the company, with no assurance any transaction will occur.
The company announced a major restructuring that will eliminate its R&D organization, reduce G&A by about 50%, and cut operating expenses by roughly 60%, or about $70 million, impacting around half of the workforce. Management expects these actions, together with YUPELRI revenue, to support approximately $60–$70 million of annualized cash flow starting in Q3 2026.
Theravance highlighted cash of $326.5 million as of December 31 2025, expected cash of about $400 million at the end of Q1 2026 after receiving a $25 million YUPELRI milestone and a $50 million TRELEGY milestone, and a potential additional $100 million TRELEGY milestone tied to 2026 global sales. YUPELRI U.S. net sales reached $266.6 million in 2025, up 12% year over year.
Theravance Biopharma, Inc. reported an insider equity transaction by Chief Executive Officer Rick E. Winningham. On the reported date, 74,975 ordinary shares were withheld at an implied price of $19.66 per share to satisfy tax obligations from the vesting of previously granted restricted stock units. This withholding was with the company and did not involve any open market trade. After the transaction, Winningham directly held 1,576,094 ordinary shares. He also had indirect holdings of 23,400 ordinary shares as custodian and 92,567 ordinary shares held by a trust.
Theravance Biopharma, Inc. executive Aziz Sawaf, SVP & Chief Financial Officer, reported a tax-related share disposition. On February 20, 2026, 20,672 Ordinary Shares were withheld at $19.66 per share to satisfy tax obligations from vesting restricted stock units. This withholding was conducted with the company and did not involve any open market trade. After this transaction, Sawaf directly held 316,123 Ordinary Shares.
Theravance Biopharma, Inc. senior vice president Aine Miller reported a tax-related share disposition linked to vesting equity awards. On the transaction date, 16,851 Ordinary Shares were withheld at a price of $19.66 per share to cover tax obligations from previously granted restricted stock units vesting. The shares were withheld by the company rather than sold in the open market, and Miller’s directly owned stake after this tax-withholding transaction was 184,161 Ordinary Shares.
Theravance Biopharma SVP Brett A. Grimaud reported a tax-related share disposition. On this Form 4, 20,833 Ordinary Shares were withheld at $19.66 per share to cover tax obligations from vesting restricted stock units. This was a transaction with the company, not an open-market trade, and left him holding 334,449 shares directly.
Theravance Biopharma, Inc. senior vice president Rhonda Farnum reported a tax-related share disposition connected to the vesting of restricted stock units. On this Form 4, 13,929 ordinary shares were withheld at a price of $19.66 per share to satisfy tax obligations, in a transaction with the issuer rather than through the open market. Following this tax-withholding event, Farnum directly owned 263,766 ordinary shares.
Theravance Biopharma, Inc. received an updated beneficial ownership report from Newtyn entities. As of December 31, 2025, Newtyn Management, LLC may be deemed to beneficially own 4,300,000 ordinary shares, representing 8.5% of the company’s ordinary shares based on 50,672,431 shares outstanding as of November 3, 2025.
Newtyn TE Partners, LP directly holds 2,678,900 ordinary shares, or 5.3% of the class, while Newtyn Partners, LP holds 1,621,100 shares, all managed by Newtyn Management. The reporting persons certify the shares were acquired and are held without the purpose or effect of changing or influencing control of Theravance Biopharma.
Theravance Biopharma, Inc. filed a Form 8-K to furnish an investor presentation under Regulation FD. Members of the management team are holding one-on-one meetings with analysts and investors in San Francisco, California from January 12–15, 2026, using a corporate slide presentation. That slide deck, entitled “Corporate Presentation – January 2026”, is provided as Exhibit 99.1 and incorporated by reference into the report.
Theravance Biopharma, Inc. (TBPH) reported an insider equity transaction by its SVP & Chief Financial Officer on 11/20/2025. The officer had 18,627 ordinary shares withheld at a price of $17.90 per share in a transaction coded "F," which indicates shares were withheld to cover tax obligations from the vesting of previously granted restricted stock units.
After this tax-withholding event, the officer directly beneficially owned 336,795 ordinary shares. The explanation clarifies that this was a share withholding with the issuer and did not involve an open market transaction.